Pillstats
Rx only · Powder, For Solution · Oral

Clindamycin Palmitate Hydrochloride

Clindamycin Palmitate Hydrochloride

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US2 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCD10AF01
RxCUI (US)2582
US makers2 labelers
Packages2
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.044$0.087$0.131$0.174Dec 2025Apr 2026Jul 2026
$0.127
Latest avg · Jul 22, 2026
-16%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

3707411.1K1.5K2025 Q12025 Q22025 Q32025 Q42026 Q1
402
Rx · 2026 Q1
110K
Units dispensed
-69%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Amneal Pharmaceuticals of New York LLCunknown1SUPPLYING
Amneal Pharmaceuticals LLCunknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Mar 26, 2026
    RESOLVEDShortage resolved: Clindamycin Palmitate Hydrochloride Injection (Amneal Pharmaceuticals)

    Clindamycin Palmitate Hydrochloride Injection — reported in shortage by Amneal Pharmaceuticals. Therapeutic category: Anti-Infective.

  • Feb 27, 2026
    SHORTAGEDrug shortage: Clindamycin Palmitate Hydrochloride Injection (Amneal Pharmaceuticals)

    Clindamycin Palmitate Hydrochloride Injection — reported in shortage by Amneal Pharmaceuticals. Therapeutic category: Anti-Infective.